LYMPHIR™ (denileukin diftitox-cxdl)
Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL)
ApprovedFDA Approved (August 2024)
Key Facts
Indication
Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL)
Phase
Approved
Status
FDA Approved (August 2024)
Company
About Citius Oncology
Citius Oncology is a clinical-stage biopharmaceutical company dedicated to advancing targeted therapies for cancer, with a strategic focus on expediting development pathways and securing competitive advantages through intellectual property and regulatory exclusivity. Its flagship achievement is the FDA approval of LYMPHIR™, a targeted immune therapy for a difficult-to-treat form of lymphoma. The company's strategy emphasizes leveraging existing clinical data and regulatory frameworks to reduce development risks and accelerate the delivery of new treatment options to patients.
View full company profile